- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals Inc stock price live, this page displays NASDAQ BCRX stock exchange data. View the BCRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the BioCryst Pharmaceuticals Inc real time stock price chart below.
What Is the BioCryst Pharmaceuticals Inc Stock Price Today?
The BioCryst Pharmaceuticals Inc stock price today is 10.565.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc?
The stock symbol for BioCryst Pharmaceuticals Inc is "BCRX."
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCRX quote. (ISIN: US09058V1035)
What Is the BioCryst Pharmaceuticals Inc Stock Price Today?
The BioCryst Pharmaceuticals Inc stock price today is 10.565.
What Is the Stock Symbol for BioCryst Pharmaceuticals Inc?
The stock symbol for BioCryst Pharmaceuticals Inc is "BCRX."
What Stock Exchange Does BioCryst Pharmaceuticals Inc Trade On?
BioCryst Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is BioCryst Pharmaceuticals Inc a Good Stock to Buy?
Determining whether BioCryst Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCRX quote. (ISIN: US09058V1035)
10.545
+0.705(+7.16%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.780
10.590
52 wk Range
6.000
11.220
BCRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.78010.590
52 wk Range
6.00011.220
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
20.818
Upside
+97.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.818
(+97.42% Upside)
BioCryst Pharmaceuticals Inc SWOT Analysis
Rare Disease Focus | BioCryst carved a distinctive position in hereditary angioedema treatment with Orladeyo, projecting growth from pediatric expansion and geographic reach |
Pediatric Breakthrough | FDA approval for children aged 2-11 unlocks an estimated $100 million market as the first oral therapy, establishing competitive advantages across patient lifecycles |
Analyst Outlook | Citi Research maintains Market Outperform rating with a $25 price target, reflecting confidence in the company's transition to profitability |
Pipeline Potential | Delve into BCX17725 development for Netherton syndrome and the Astria acquisition, which could diversify revenue beyond Orladeyo toward the ambitious $1.8 billion target by 2033 |
BioCryst Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- BioCryst Q2 2026 EPS of $0.30 beat estimates by 87.5%; revenue of $218.3M topped forecasts by 17.56%, driven by ORLADEYO and licensing payment.
- Full-year revenue guidance raised to $690M-$715M; operating costs lowered to $420M-$440M from $454M-$470M amid restructuring and site closure.
- ORLADEYO generated $158.2M, up 10% year-over-year; company ended quarter with over $350M cash, strongest balance sheet to date.
- Company halting internal drug discovery, closing Birmingham site by year-end; shifting to external innovation model for pipeline development.
- Navenibart pivotal study enrollment complete with top-line data expected Q3 2027; BCX17725 Netherton syndrome data due by end of 2026.
Last Updated: 08/05/2026, 09:18 PM
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
0.30 / 0.16
Revenue / Forecast
218.3M / 185.69M
Compare BCRX to Peers and Sector
Metrics to compare | BCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | 9.2x | −0.4x | |
PEG Ratio | 0.01 | 0.20 | 0.00 | |
Price/Book | −5.9x | 1.4x | 2.6x | |
Price / LTM Sales | 2.8x | 2.3x | 3.1x | |
Upside (Analyst Target) | 72.5% | 25.8% | 48.2% | |
Fair Value Upside | Unlock | 5.4% | 5.8% | Unlock |
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the BioCryst (BCRX) Stock Price Today?
The BioCryst stock price today is 10.545 USD.
What Stock Exchange Does BioCryst Trade On?
BioCryst is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BioCryst?
The stock symbol for BioCryst is "BCRX."
What Is the BioCryst Market Cap?
As of today, BioCryst market cap is 2.670B USD.
What Is BioCryst's Earnings Per Share (TTM)?
The BioCryst EPS (TTM) is -1.676.
When Is the Next BioCryst Earnings Date?
BioCryst will release its next earnings report on Nov 04, 2026.
From a Technical Analysis Perspective, Is BCRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has BioCryst Stock Split?
BioCryst has split 0 times.
How Many Employees Does BioCryst Have?
BioCryst has 435 employees.
What is the current trading status of BioCryst (BCRX)?
As of Aug 11, 2026, BioCryst (BCRX) is trading at a price of 10.545 USD, with a previous close of 9.840 USD. The stock has fluctuated within a day range of 9.780 USD to 10.590 USD, while its 52-week range spans from 6.000 USD to 11.220 USD.
What Is BioCryst (BCRX) Price Target According to Analysts?
The average 12-month price target for BioCryst is 20.818 USD, with a high estimate of 32 USD and a low estimate of 12 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +97.42% Upside potential.
What Is the BCRX Premarket Price?
BCRX's last pre-market stock price is 9.870 USD. The pre-market share volume is 1,630.000, and the stock has decreased by 0.030, or 0.300%.
What Is the BCRX After Hours Price?
BCRX's last after hours stock price is 9.720 USD, the stock has decreased by -0.120, or -1.220%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.